Clinical trialNCT04556773Active, not recruitingPhase 1Interventional

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

SponsorAstraZenecaEnrollment138Metastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Melbourne, Australia
Research Site
Westmead, Australia

Belgium

Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Ottignies, Belgium

Brazil

Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Canada

Research Site
Kelowna, British Columbia, Canada
Research Site
Québec, Quebec, Canada

France

Research Site
Villejuif, France

Mexico

Research Site
Monterrey, Mexico

Russia

Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Saint Petersburg, Russia

South Korea

Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea

Taiwan

Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan

United States

Research Site
Commack, New York, United States
Research Site
Harrison, New York, United States
Research Site
New York, New York, United States
Research Site
New York, New York, United States
Research Site
Uniondale, New York, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Germantown, Tennessee, United States
Research Site
Fort Worth, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anastrozole →Capecitabine →Capivasertib →Durvalumab →Fulvestrant →Paclitaxel →Trastuzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Dec 2020
Primary completion: 16 Aug 2023
Completion: 1 Jun 2027
Last update posted: 3 Aug 2026
Registered enrollment: 138
Registry id: NCT04556773

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-002797-27EU-CTR / CTIS (EudraCT)2023-505690-33-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.